A rising interest in the neurodegenerative (ND) disease space has sparked a flurry of high-money deals, with the last three years indicating a doubling in the number of collaborations and licensing agreements, plus an 87 percent incline in deal value, when compared to the previous three years. Read More
Recombinant clotting factors have been the mainstay treatments for hemophilia, but there are a growing number of companies developing hemophilia drugs using novel mechanisms of action. Those companies will get a look at the competition later this month at the International Society on Thrombosis and Haemostasis (ISTH) conference as they vie for patients with unmet needs, including those with antibodies that inhibit the clotting factors and as treatments that can be used for prophylaxis. Read More